Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors

Michael Bots, Inge Verbrugge, Benjamin P. Martin, Jessica M. Salmon, Margherita Ghisi, Adele Baker, Kym Stanley, Jake Shortt, Gert J. Ossenkoppele, Johannes Zuber, Amy R. Rappaport, Peter Atadja, Scott W. Lowe, Ricky W. Johnstone

Blood (2014) 123 (9): 1341–1352.

https://doi.org/10.1182/blood-2013-03-488114

Published: 2014

Includes: Supplemental data

Journal Articles

Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists

Aditya Mandawat, Warren Fiskus, Kathleen M. Buckley, Kelly Robbins, Rekha Rao, Ramesh Balusu, Jean-Marc Navenot, Zi-Xuan Wang, Celalettin Ustun, Daniel G. Chong, Peter Atadja, Nobutaka Fujii, Stephen C. Peiper, Kapil Bhalla

Blood (2010) 116 (24): 5306–5315.

https://doi.org/10.1182/blood-2010-05-284414

Published: 2010

Journal Articles

Efficacy of Combined Epigenetic Targeting of Histone Methyltransferase EZH2 and Histone deacetylases Against Human Mantle Cell Lymphoma Cells

Warren Fiskus, BSc, PhD, Rekha Rao, Ramesh Balusu, Jianguo Tao, MD, PhD, Eduardo M. Sotomayor, MD, Peter Atadja, Kapil N. Bhalla, MD

Blood (2010) 116 (21): 2488.

https://doi.org/10.1182/blood.V116.21.2488.2488

Published: 2010

Journal Articles

IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms

Elke De Bruyne, Tomas J. Bos, Frans Schuit, Els Van Valckenborgh, Eline Menu, Lieven Thorrez, Peter Atadja, Helena Jernberg-Wiklund, Karin Vanderkerken

Blood (2010) 115 (12): 2430–2440.

https://doi.org/10.1182/blood-2009-07-232801

Published: 2010

Includes: Supplemental data

Journal Articles

Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells

Yongchao Wang, Warren Fiskus, Daniel G. Chong, Kathleen M. Buckley, Kavita Natarajan, Rekha Rao, Atul Joshi, Ramesh Balusu, Sanjay Koul, Jianguang Chen, Andrew Savoie, Celalettin Ustun, Anand P. Jillella, Peter Atadja, Ross L. Levine, Kapil N. Bhalla

Blood (2009) 114 (24): 5024–5033.

https://doi.org/10.1182/blood-2009-05-222133

Published: 2009

Includes: Supplemental data

Journal Articles

Novel SIRT1 Agonists, SRT501 and SRT2183, Induce Expression of DNA Repair Genes and Apoptosis of Ph − Acute Lymphoblastic Leukemia Cells Alone and in Combination with the HDAC Inhibitor LBH589..

Anna Scuto, Mark Kirschbaum, MD, Jennifer M Cermak, Peter Atadja, Richard Jove

Blood (2009) 114 (22): 3083.

https://doi.org/10.1182/blood.V114.22.3083.3083

Published: 2009

Journal Articles

Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells

Warren Fiskus, Yongchao Wang, Arun Sreekumar, Kathleen M. Buckley, Huidong Shi, Anand Jillella, Celalettin Ustun, Rekha Rao, Pravina Fernandez, Jianguang Chen, Ramesh Balusu, Sanjay Koul, Peter Atadja, Victor E. Marquez, Kapil N. Bhalla

Blood (2009) 114 (13): 2733–2743.

https://doi.org/10.1182/blood-2009-03-213496

Published: 2009

Includes: Supplemental data

Journal Articles

The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy

Leigh Ellis, Michael Bots, Ralph K. Lindemann, Jessica E. Bolden, Andrea Newbold, Leonie A. Cluse, Clare L. Scott, Andreas Strasser, Peter Atadja, Scott W. Lowe, Ricky W. Johnstone

Blood (2009) 114 (2): 380–393.

https://doi.org/10.1182/blood-2008-10-182758

Published: 2009

Includes: Supplemental data

Journal Articles

Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77–based mechanism

Jianguang Chen, Warren Fiskus, Kelly Eaton, Pravina Fernandez, Yongchao Wang, Rekha Rao, Pearl Lee, Rajeshree Joshi, Yonghua Yang, Ravindra Kolhe, Ramesh Balusu, Prasanthi Chappa, Kavita Natarajan, Anand Jillella, Peter Atadja, Kapil N. Bhalla

Blood (2009) 113 (17): 4038–4048.

https://doi.org/10.1182/blood-2008-08-176024

Published: 2009

Includes: Supplemental data

Journal Articles

Anti-AML Activity of Combined Epigenetic Therapy with Novel DNMT1 Inhibitors SGI-110 or SGI-1036 and Histone Deacetylase Inhibitor Panobinostat.

Warren Fiskus, Pace Johnston, Rajeshree Joshi, Rekha Rao, Celalettin Ustun, Anand Jillella, Peter Atadja, Stuart Hwang, Sanjeev Redkar, Kapil N. Bhalla

Blood (2008) 112 (11): 3355.

https://doi.org/10.1182/blood.V112.11.3355.3355

Published: 2008

Journal Articles

Co-Treatment with Panobinostat Enhances Bortezomib-Induced Unfolded Protein Response, Endoplasmic Reticulum Stress and Apoptosis of Human Mantle Cell Lymphoma Cells

Rekha Rao, Warren Fiskus, Yonghua Yang, Rajeshree Joshi, Pravina Fernandez, Pearl Lee, Anand Jillella, Jianguo Tao, Peter Atadja, Eduardo Sotomayor, Kapil N. Bhalla

Blood (2008) 112 (11): 887.

https://doi.org/10.1182/blood.V112.11.887.887

Published: 2008

Journal Articles

Combined Epigenetic Therapy with the Novel Histone Methyl Transferase EZH2 Inhibitor 3-Deazaneplanocin and Histone Deacetylase Inhibitor Panobinostat Exerts Synergistic Activity against Human Mantle Cell Lymphoma Cells

Warren Fiskus, Yongchao Wang, Anand Jillella, Pace Johnston, Rajeshree Joshi, Rekha Rao, Eduardo Sotomayor, Jianguo Tao, Peter Atadja, Victor Marqez, Kapil N. Bhalla

Blood (2008) 112 (11): 3622.

https://doi.org/10.1182/blood.V112.11.3622.3622

Published: 2008

Journal Articles

Panobinostat (LBH589) a Promising New Partner for Combination with Doxorubicin in Acute Myeloid Leukemia.

Patricia Maiso, Enrique Colado, Enrique M Ocio, Mercedes Garayoa, Peter Atadja, Atanasio Pandiella, J. F. San Miguel, MD, PhD

Blood (2008) 112 (11): 1638.

https://doi.org/10.1182/blood.V112.11.1638.1638

Published: 2008

Journal Articles

Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor–resistant acute myeloid leukemia cells

Warren Fiskus, Rekha Rao, Pravina Fernandez, Bryan Herger, Yonghua Yang, Jianguang Chen, Ravindra Kolhe, Aditya Mandawat, Yongchao Wang, Rajeshree Joshi, Kelly Eaton, Pearl Lee, Peter Atadja, Stephen Peiper, Kapil Bhalla

Blood (2008) 112 (7): 2896–2905.

https://doi.org/10.1182/blood-2007-10-116319

Published: 2008

Journal Articles

HDAC6 inhibition enhances 17-AAG–mediated abrogation of hsp90 chaperone function in human leukemia cells

Rekha Rao, Warren Fiskus, Yonghua Yang, Pearl Lee, Rajeshree Joshi, Pravina Fernandez, Aditya Mandawat, Peter Atadja, James E. Bradner, Kapil Bhalla

Blood (2008) 112 (5): 1886–1893.

https://doi.org/10.1182/blood-2008-03-143644

Published: 2008

Journal Articles

The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph − acute lymphoblastic leukemia cells

Anna Scuto, Mark Kirschbaum, Claudia Kowolik, Leo Kretzner, Agnes Juhasz, Peter Atadja, Vinod Pullarkat, Ravi Bhatia, Stephen Forman, Yun Yen, Richard Jove

Blood (2008) 111 (10): 5093–5100.

https://doi.org/10.1182/blood-2007-10-117762

Published: 2008

Includes: Supplemental data

Journal Articles

Efficacy of Panobinostat (LBH589) in Multiple Myeloma Cell Lines and In Vivo Mouse Model: Tumor-Specific Cytotoxicity and Protection of Bone Integrity in Multiple Myeloma.

Joseph D. Growney, PhD, Peter Atadja, PhD, Wenlin Shao, PhD, Youzhen Wang, PhD, Minying Pu, MD, Brant Firestone, BS, Jane Cheng, MS, Colleen Kowal, BS, Christine Miller, BS, Joseph Eckman, BS, Yung-Mae Yao, PhD, Stephen Fawell, PhD, Andrew Spencer, MD, Jesus F. San Miguel, MD, Kenneth C. Anderson, MD

Blood (2007) 110 (11): 1510.

https://doi.org/10.1182/blood.V110.11.1510.1510

Published: 2007

Journal Articles

Triple Combinations of the HDAC Inhibitor Panobinostat (LBH589) + Dexamethasone with Either Lenalidomide or Bortezomib Are Highly Effective in a Multiple Myeloma Mouse Model.

Enrique M. Ocio, MD, PhD, David Vilanova, BS, Laura San-Segundo, BS, Patricia Maiso, BS, PhD, Mercedes Garayoa, BS, PhD, Peter Atadja, Atanasio Pandiella, MD, PhD, J.F. San Miguel, MD, PhD

Blood (2007) 110 (11): 1514.

https://doi.org/10.1182/blood.V110.11.1514.1514

Published: 2007

Journal Articles

Pan-Histone Deacetylase (HDAC) Inhibitor LBH589 Depletes CXCR4 Levels and Signaling, Exerting Synergistic Anti-Leukemia Activity in Combination with CXCR4 Antagonists.

Aditya Mandawat, BS, Warren Fiskus, PhD, Andrea Jakubowski, Rekha Rao, PhD, Zixuan Wang, PhD, Pravina Fernandez, MS, Yongchao Wang, MS, Pearl Lee, BS, Anand Jillela, MD, Peter Atadja, PhD, Nobutaka Fujii, PhD, Stephen C. Peiper, MD, Kapil Bhalla, MD

Blood (2007) 110 (11): 537.

https://doi.org/10.1182/blood.V110.11.537.537

Published: 2007

Journal Articles

Regulation of Bim Expression by IGF-1 in the 5T33MM Murine Model for Multiple Myeloma.

Elke De Bruyne, Tomas Bos, Sarah Deleu, Peter Atadja, PhD, Eline Menu, PhD, Els Van Valckenborgh, PhD, Ben Van Camp, MD, PhD, Karin Vanderkerken, PhD

Blood (2007) 110 (11): 3512.

https://doi.org/10.1182/blood.V110.11.3512.3512

Published: 2007

NARROW

Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors

Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists

Efficacy of Combined Epigenetic Targeting of Histone Methyltransferase EZH2 and Histone deacetylases Against Human Mantle Cell Lymphoma Cells

IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms

Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells

Novel SIRT1 Agonists, SRT501 and SRT2183, Induce Expression of DNA Repair Genes and Apoptosis of Ph − Acute Lymphoblastic Leukemia Cells Alone and in Combination with the HDAC Inhibitor LBH589..

Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells

The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy

Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77–based mechanism

Anti-AML Activity of Combined Epigenetic Therapy with Novel DNMT1 Inhibitors SGI-110 or SGI-1036 and Histone Deacetylase Inhibitor Panobinostat.

Co-Treatment with Panobinostat Enhances Bortezomib-Induced Unfolded Protein Response, Endoplasmic Reticulum Stress and Apoptosis of Human Mantle Cell Lymphoma Cells

Combined Epigenetic Therapy with the Novel Histone Methyl Transferase EZH2 Inhibitor 3-Deazaneplanocin and Histone Deacetylase Inhibitor Panobinostat Exerts Synergistic Activity against Human Mantle Cell Lymphoma Cells

Panobinostat (LBH589) a Promising New Partner for Combination with Doxorubicin in Acute Myeloid Leukemia.

Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor–resistant acute myeloid leukemia cells

HDAC6 inhibition enhances 17-AAG–mediated abrogation of hsp90 chaperone function in human leukemia cells

The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph − acute lymphoblastic leukemia cells

Efficacy of Panobinostat (LBH589) in Multiple Myeloma Cell Lines and In Vivo Mouse Model: Tumor-Specific Cytotoxicity and Protection of Bone Integrity in Multiple Myeloma.

Triple Combinations of the HDAC Inhibitor Panobinostat (LBH589) + Dexamethasone with Either Lenalidomide or Bortezomib Are Highly Effective in a Multiple Myeloma Mouse Model.

Pan-Histone Deacetylase (HDAC) Inhibitor LBH589 Depletes CXCR4 Levels and Signaling, Exerting Synergistic Anti-Leukemia Activity in Combination with CXCR4 Antagonists.

Regulation of Bim Expression by IGF-1 in the 5T33MM Murine Model for Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only